Partnership expected to utilize Walgreens’ pharmacies as recruitment and trial sites for a clinical study regarding obesity, ...

Currently in Phase III of clinical trials, eneboparatide has shown promise in normalizing key calcium levels and improving ...

The move targets over 300 listings for 20 branded products from companies such as AstraZeneca, Novo Nordisk, and GSK that the ...

In this Pharmaceutical Executive video interview, Jesse Mendelsohn, senior vice president at Model N, discusses the changing ...

The vice president of technology strategy & strategic partnerships at Syneos Health discusses how new digital technologies ...

Approval of Tivdak was based on promising results from a Phase III innovaTV 301 clinical trial, which demonstrated a 30% ...

In this Pharmaceutical Executive video interview, Chris Martin, Chief Commercial Officer, Verona Pharma, discusses specific ...

Treatment marks the first dissolving stent approved in the United States for treating chronic limb-threatening ischemia in ...

Jennifer Hawks Bland, CEO of NewYorkBIO, spoke with Pharmaceutical Executive about current market trends that investors are ...

Approval of Libervant marks the first orally administered rescue medication for this age group to be cleared by the FDA for ...

Currax Pharmaceuticals CEO, George Hampton discusses what patient success has looked like for their oral anti-obesity ...

Beqvez, a one-time gene therapy, offers hope to patients with moderate to severe hemophilia B who use regular factor IX ...